View this email in your browser ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­ ͏ ‌     ­
webversion | unsubscribe | update profile
‌
Issue 151: September 22, 2023
‌
new-briefing-header-1
 

NDEWS ORIGINAL CONTENT

 

Question for the community

In your area, how effective is increasing the dosage of buprenorphine for opioid use disorder to maintain people in treatment?
share-your-thoughts-01
 

RECENTLY PUBLISHED

 
screenshot-502

Signals report: Xylazine

Last week, Millennium Health published its Signals report. According to the report, xylazine has been detected in urine drug tests from every region of the country, with highest rates in the Eastern US. The report includes more than 160,000 drug tests, with xylazine, fentanyl, and other potentially lethal substances frequently found together. Read the report here.
share-your-thoughts-01
twitter-button-01

Evidence of housing instability identified by addresses, clinical notes, and diagnostic codes in a real-world population with substance use disorders

A recently published study identified evidence of housing instability using structured and unstructured clinical data from electronic health records to improve translational research on populations with substance use disorders. Read the study here.
share-your-thoughts-01
twitter-button-01
 

IN THE NEWS

 

Overdose deaths continue to rise in the US, reaching another record level, provisional data shows

An article published this week by CNN highlighted new provisional drug overdose data from the US Centers for Disease Control and Prevention (CDC). The latest data shows that through April, a thousand more lives were lost in the past 12 months than in the year before. According to the provisional data from the CDC, fentanyl and other synthetic opioids are involved in nearly 70% of overdose deaths. Read the article here.
share-your-thoughts-01
twitter-button-01
 

UPCOMING WEBINARS

 
screenshot-483

NMS Labs: Preparing for the 2023 Farm Act: Proactive Collaboration for Laboratory Success

Presenters: Aliece Watts, Quality Assurance Regulatory Manager, NMS Labs
Nicole Lattanzio, Forensic Chemistry Technical Director, NMS Labs
Ryan White, Senior Product Manager, NMS Labs
Date: Wednesday, September 27, 2023
Time: 1:30 – 2:30 p.m. ET

On Wednesday, September 27th, 2023, at 1:30 – 2:30 p.m. ET, NMS Labs will discuss how to create a proactive approach for successfully navigating legislative changes through multi-departmental collaboration, communication, and support. During the webinar, attendees will learn the necessity of monitoring, understanding, and planning for legislative changes (such as with the Federal Farm Act) to support public health and safety through offering appropriate testing options.

Register here.
screenshot-504

Quarterly NPS Discovery Webinar Series

The Center for Forensic Science Research & Education's NPS Discovery has just announced their second iteration of their new quarterly webinar series. Each webinar will begin with a review of the newest trend reports, followed by presentations that cover topics related to forensic toxicology, forensic chemistry, clinical toxicology, analytical chemistry, and more.

The series will be held Thursday, October 12th, 2023 from 11 a.m. – 12:30 p.m. ET

Register here.
ndews-submission-form-graphic-6
 

Get in Touch with NDEWS

Share your research, news, and events through our submission form

Share your comments on our newsletter through our feedback form

Follow NDEWS on Twitter: @NDEWSnews

 
Orange w Bar (2)
Email_Footer
‌


The Weekly Briefing is a newsletter published each week by the National Drug Early Warning System (NDEWS) Coordinating Center, which is funded by the National Institute on Drug Abuse (U01DA051126) to the University of Florida (PI: Cottler, Co-Is: Goldberger, Nixon, Striley), New York University (Co-I: Palamar), and Florida Atlantic University (Co-I: Barenholtz). Any item may be reproduced provided the source is acknowledged.
Copyright © 2023 National Drug Early Warning System (NDEWS), All rights reserved.
‌